^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersBIOMARKER:
BRAF mutation
i
Other names: BRAF, B-raf proto-oncogene, B-raf proto-oncogene, Serine/threonine kinase, V-Raf murine sarcoma viral oncogene homolog B, Serine/threonine-protein kinase B-Raf, Proto-oncogene B-Raf, BRAF1, RAFB1, B-raf proto-oncogene Serine/threonine-protein kinase, Murine sarcoma viral (V-Raf) oncogene homolog B1, B-raf serine/threonine-protein, 94 KDa B-raf protein, B-RAF1
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
Related tests:
2d
Case Report: A case of superficial spreading malignant melanoma with sentinel lymph node metastasis misdiagnosed as "pigmented nevus". (PubMed, Front Immunol)
Postoperative adjuvant therapy included systemic chemotherapy and targeted therapy. No recurrence was observed during the 2-year follow-up period.
Journal
|
BRAF (B-raf proto-oncogene) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • TERT (Telomerase Reverse Transcriptase) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • SOX10 (SRY-Box 10) • MLANA (Melan-A)
|
BRAF mutation
2d
A Study in People With Advanced Cancer (Solid Tumours) to Test Different Doses of BI 3810944 and to Find Out Whether it Helps (clinicaltrials.gov)
P1, N=69, Recruiting, Boehringer Ingelheim | Not yet recruiting --> Recruiting
Enrollment open • First-in-human
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation
2d
EAY131-Z1K: Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K) (clinicaltrials.gov)
P2, N=35, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Jan 2027
Trial completion date
|
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog)
|
BRAF mutation • HRAS mutation
|
ipatasertib (RG7440)
2d
A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=542, Recruiting, Sanofi | Not yet recruiting --> Recruiting
Enrollment open • First-in-human
|
BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
|
BRAF mutation • HER-2 negative • RAS mutation
|
Opdivo (nivolumab) • Avastin (bevacizumab) • Erbitux (cetuximab) • Yervoy (ipilimumab) • SAR445877 • muzastotug (ADG126)
3d
Izalontamab Brengitecan in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations Outside of Classical EGFR Mutations: A Phase Ib Study. (PubMed, J Clin Oncol)
iza-bren demonstrated encouraging antitumor activity and a manageable safety profile in pretreated NSCLC patients with diverse GAs outside of classical EGFR mutations, especially in EGFR exon20ins/nonclassical and HER2 mutations.
P1 data • Journal
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
|
KRAS mutation • EGFR mutation • BRAF mutation • RET fusion • EGFR exon 20 insertion • RET mutation • ROS1 fusion • MET mutation • EGFR exon 20 mutation • NTRK fusion
|
izalontamab (SI-B001) • izalontamab brengitecan (BL-B01D1)
3d
Comparison of [18F]PFPN and [18F]FDG PET in mucosal melanoma: diagnostic performance, staging impact, and correlation with molecular markers. (PubMed, Clin Cancer Res)
[18F]PFPN PET outperforms [18F]FDG PET in lesion detection and clinical staging in mucosal melanoma, especially for liver and bone metastases. Its association with melanin differentiation markers may support its use in personalized imaging strategies.
Journal
|
BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • SOX10 (SRY-Box 10)
|
BRAF mutation • NRAS mutation
3d
Case Report: Membranous/cytoplasmic Ki-67 staining and PAX8-GLIS3 fusion: defining the clinicopathological spectrum of hyalinizing trabecular tumor to optimize patient management. (PubMed, Front Med (Lausanne))
The use of Ki-67 immunohistochemistry or PAX8-GLIS3 testing on cytological specimens can aid in definitive diagnosis and prevent unnecessary surgery. Thus, an integrated approach combining cytological, histological, immunohistochemical, and molecular data is essential for the accurate diagnosis and optimal clinical management of HTT.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • NRAS (Neuroblastoma RAS viral oncogene homolog) • TTF1 (Transcription Termination Factor 1) • NCAM1 (Neural cell adhesion molecule 1) • NKX2-1 (NK2 Homeobox 1) • PAX8 (Paired box 8)
|
BRAF mutation • PIK3CA mutation
3d
A Phase II Trial of LM103 in Advanced Melanoma (clinicaltrials.gov)
P2, N=92, Recruiting, Suzhou BlueHorse Therapeutics Co., Ltd. | Not yet recruiting --> Recruiting
Enrollment open
|
BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
|
BRAF mutation • NRAS mutation • BRAF V600
|
cisplatin • carboplatin • paclitaxel • temozolomide • dacarbazine • LM103
3d
Phase I/II clinical trial of a melanoma vaccine targeting shared non-mutated antigens and a shared mutated BRAF neoantigen with an agonistic CD40 antibody (CDX-1140) plus TLR3 agonist (poly-ICLC). (PubMed, J Immunother Cancer)
The vaccine was safe, well-tolerated, and immunogenic. Optimization of vaccines that include agonistic CD40 antibody is needed to enhance immunogenicity. Induction of a multifunctional CD4+ T cell response to mBRAF supports targeting shared mutated neoantigens with melanoma vaccines.
P1/2 data • Journal • IO biomarker • First-in-human
|
BRAF (B-raf proto-oncogene) • CD8 (cluster of differentiation 8) • LAMP3 (Lysosomal Associated Membrane Protein 3) • CD40 (CD40 Molecule)
|
BRAF V600E • BRAF mutation • BRAF V600
|
CDX-1140 • Hiltonol (poly-ICLC)
5d
A Study to Assess a Medicine Called Tovorafenib in Japanese Children and Young Adults With Brain Tumours (clinicaltrials.gov)
P1, N=6, Not yet recruiting, Ipsen
New P1 trial
|
BRAF (B-raf proto-oncogene) • KIAA1549
|
BRAF mutation • BRAF V600 • BRAF fusion
|
Ojemda (tovorafenib)
5d
DCC-3084-01-001: Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway (clinicaltrials.gov)
P1, N=29, Terminated, Deciphera Pharmaceuticals, LLC | Phase classification: P1/2 --> P1 | N=140 --> 29 | Trial completion date: Aug 2027 --> Feb 2026 | Active, not recruiting --> Terminated | Trial primary completion date: Aug 2026 --> Feb 2026; Trial terminated due to a business decision, not based on any safety concerns.
Phase classification • Enrollment change • Trial completion date • Trial termination • Trial primary completion date
|
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog) • NF1 (Neurofibromin 1) • RAF1 (Raf-1 Proto-Oncogene Serine/Threonine Kinase)
|
BRAF mutation
|
DCC-3084
5d
Swiss-PO 2025: Advancing Cancer Mutation and Structural Analysis for Precision Oncology With the Latest Release. (PubMed, JCO Precis Oncol)
With these enhancements, Swiss-PO strengthens its role as a powerful and versatile resource for oncologists, bioinformaticians, and molecular biologists engaged in the interpretation of cancer-associated mutations and the advancement of precision medicine. The website is available at Swiss-PO.
Journal
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation
Share via
